Translational Biomarkers Header 

May 6-7



Translational Biomarkers in Drug Discovery

Enabling Robust Biomarker-Driven Decision Making in Drug Development: Key Factors and Considerations

Michael E. (Ransom) Burczynski, Ph.D., Executive Director, Biomarker Technologies, Exploratory Clinical and Translational Research, Bristol-Myers Squibb

Talk Title to be Announced

Suso Platero, Ph.D., Director, Oncology Biomarkers, Janssen Pharmaceuticals

Current Status for AD Biomarkers: From Mice to Men to Trials and Clinical Practice

Johan Luthman, D.D.S., Ph.D., Vice President, Neuroscience Clinical Development, Eisai

Approaches to Biomarkers “that can Translate the Stubbornness of Fortune”

William B. Mattes, Ph.D., DABT, Director, Division of Systems Biology, National Center for Toxicological Research, US Food and Drug Administration

Consumer Genetics: What Role in Drug Discovery and Development?

Stephen T. Furlong, Ph.D., Safety Science Lead, AstraZeneca

Lessons from Thalidomide and IMiD drugs in the Development of Biomarkers

Rajesh Chopra, M.D., Ph.D., Corporate Vice President, Translational Integration, Celgene


NGS-Driven Clinical Trials

MSK-IMPACT: Clinical Experience with High Volume Hybrid Capture-Based Next-Generation Sequencing to Enable Personalized Oncology and Prepopulate Genetically Informed Clinical Trials

Marc Ladanyi, M.D., William Ruane Chair in Molecular Oncology, Molecular Diagnostics Service and Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center

Bringing the Power of Genomics and Next-Generation Sequencing to the NCI Clinical Trials

Daniel Edelman, Ph.D., Core Manager, Clinical Molecular Profiling Core, National Cancer Institute, NIH

Opportunities and Challenges for NGS-Based Clinical Trials

Jamie L. Platt, Ph.D., Vice President, Genomic Solutions, Geneuity (an MPLN company)

Considerations for the Use of Comprehensive Genomic Profiling in Oncology Clinical Care and Clinical Trials

Roman Yelensky, Ph.D., Senior Director, Biomarker and Companion Diagnostics Development, Foundation Medicine

Supporting Clinical Trials and Clinical Decision Making through Genomic Sequencing

Jennifer J.D. Morrissette, Ph.D., Clinical Director, Center for Personalized Diagnostics, University of Pennsylvania School of Medicine


Clinical Biomarker Assay Development

Development and Validation of a Clinical Biomarker Assay to Quantitate Thymic Stromal Lymphopoietin in Human Plasma at Sub-pg/mL level

Xuemei Zhao, Ph.D., Principal Scientist, Molecular Biomarkers and Diagnostics Laboratory, Merck


Register Today 

BMC_2014_Final 

Premier Sponsor

 Soma Logic large 

View All Sponsors 

View Media Sponsors